The o2h Human Health Funds ventures
Founded in 2018, o2h Ventures is a UK-based venture capital firm focused on investing in the next generation of biotech companies that are working to improve human health. Headquartered in Cambridge, o2h Ventures has invested over $10 million into more than 35 early-stage life science companies, with a particular focus on novel therapeutics and emerging technologies like AI and machine learning.
Many of the companies backed by o2h are tackling diseases with high unmet medical need—such as cancer, depression, infectious diseases, and age-related conditions—and several are university spinouts from institutions including Cambridge, Oxford, UCL, Dundee, and Nottingham.
o2h Ventures takes a hands-on approach, often leading investment rounds and supporting its portfolio companies through Board positions. The firm is authorised by the FCA and continues to invest from its tax-efficient funds into seed & pre-seed biotech companies that are now progressing toward commercial maturity and long-term impact.
Seed to IPO 39x upon first listing TSX V:DMT
The UK is the biggest life science innovation hub in Europe o2h Ventures is headquartered in Cambridge, and we are housed in the Mill SciTech Park, which is wholly owned by the o2h Group. Our site is in close proximity to Cambridge University, The Wellcome Genome Campus, Babraham Institute, Astra Zeneca’s HQ, Moderna and one of the largest and best-known teaching hospitals in the UK: Addenbrookes Hospital.
The UK is a highly concentrated biotech cluster of which Cambridge UK is at the epicentre. Themes include AI-driven discovery platforms, next-gen small molecules, RNA Biology, psychedelics, Antibody Drug Conjugates, Immune Oncology, Lipid Nanoparticles, and Protein Degradation.
The Mansion House Compact, July 2023 a commitment by major UK pension funds to invest 5% of the $4.3 Trillion they hold into unlisted equities which could lead to significant further late-stage capital into Biotechnology companies.
The UK retained its position as Europe’s leading biotech hub, attracting 37% of total VC investment across the continent in 2024.
The UK recevies
41% of all Biotech fundind across Europe*
Developing IP for global markets with a lower people & infrastructure costs and lower valuations than the USA.